{"title":"The Changing Landscape of Hematological <br> Malignancy Treatment","markdown":{"yaml":{"format":{"revealjs":{"touch":true,"controls":true,"transition":"fade","transition-speed":"fast","scrollable":true,"slide-number":true,"incremental":true,"multiplex":true,"chalkboard":true,"theme":["default","custom.scss"]}},"bibliography":"references.bib"},"headingText":"The Changing Landscape of Hematological <br> Malignancy Treatment","headingAttr":{"id":"","classes":[],"keyvalue":[["background-image","bonemarrow.png"]]},"containsRefs":false,"markdown":"\n\n\n<br>\n\n### Implications for antifungal therapy\n\n<br> <br>\n\n<center>Russell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> Infectious Diseases Unit- IRCCS S. Orsola University Hospitals <br> Alma Mater Studiorum Università di Bologna <br> Bologna, Italy</center>\n\n::: aside\nNovember 16, 2022\n:::\n\n## Agenda\n\n<br>\n\n-   How will new therapies for hematological malignancies impact the epidemiology of invasive fungal infections?\n-   What are the risks of toxicity and drug interactions with these newer therapies?\n-   Is their a unique role for isavuconazole vs. other triazoles?\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease                                | Current/future therapies\\*                                                                                                                                     | Survival (5 year) |\n|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|\n| **Hairy cell leukemia**                | Cladarabine + [gemtuzumab ozogamicin (GO)]{style=\"color:red;\"}                                                                                                 | 90%               |\n| **Acute premyelocytic leukemia**       | ATRA + arsenic ± [GO]{style=\"color:red;\"}                                                                                                                      | 80-90%            |\n| **AML (core binding factor positive)** | FLAG-[GO]{style=\"color:red;\"} ± IDA, alloHCT if MRD positive, if indicated, oral [AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors]{style=\"color:red;\"} | 80-90%+           |\n| **AML** <br>**(younger fit)**          | FLAG-IDA and [venetoclax]{style=\"color:red;\"}, CLIA and [venetoclax]{style=\"color:red;\"}                                                                       | 50-60%            |\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\nHMA- hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease                                                                   | Current/ future therapy\\*                                                                                                                   | 5-10 year survival |\n|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------|\n| **AML** <br> **(older, unfit, complex karyotype, T-53 mutations, MECOM)** | Low-intensity triple nucleosides (cladarabine, cytarabine and [HMAs + venetoclax; HMAs + venetoclax + targeted therapy]{style=\"color:red;\"} | 40-50%             |\n| **ALL \\< 60 years**                                                       | HyperCVAD + [CD19/CD20 targeted antibodies]{style=\"color:red;\"}                                                                             | 60-70%             |\n| **ALL \\> 60 years**                                                       | Mini-hyper CVAD+ [inotuzumab; blinatumab + ponatinib]{style=\"color:red;\"}                                                                   | 50%                |\n| **Ph-positive ALL**                                                       | HyperCVAD + [ponatinib; blinatumab + ponatinib]{style=\"color:red;\"}                                                                         | 70-80%?            |\n|                                                                           |                                                                                                                                             |                    |\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\nHMA-hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease | Current/ future therapy\\*                                                                                                 | 5-10 year survival |\n|---------|---------------------------------------------------------------------------------------------------------------------------|--------------------|\n| **CML** | [BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)]{style=\"color:red;\"}, alloHCT | 85-90%             |\n| **CLL** | [Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)]{style=\"color:red;\"}                                 | 80-90% +           |\n| **MDS** | [Parenteral HMAs, oral HMAs, venetoclax, others]{style=\"color:red;\"}                                                      | 40% +              |\n\n::: aside\n[@kantarjian2021] <br>\n\nBTKI- Bruton tyrosine kinase inhibitors, HMA- hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## <br> <br> <br> <br> <br>How is invasive fungal disease risk altered <br> by targeted therapies? {background-image=\"bonemarrow.png\"}\n\n## Unexpected consequences of targeted therapy?\n\n<br>\n\n![](burger_NEJM.png){fig-align=\"center\" width=\"3028\"}\n\n::: aside\n[@burger2015; @chamilos2018]\n:::\n\n## Ibrutinib-associated aspergillosis\n\n::: columns\n::: {.column width=\"50%\"}\n<br>\n\n<div>\n\n![](MRI.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"50%\"}\n<br>\n\n<br>\n\n-   Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL\n-   [CNS aspergillosis in 11/27 (40%)]{style=\"color:red;\"}, most cases within 3 months of starting therapy\n-   All patients had refractory/relapsed CLL and other predisposing risk factors\n:::\n:::\n\n::: aside\n[@ghez2018; @chamilos2018]\n:::\n\n## Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers\n\n::: columns\n::: {.column width=\"60%\"}\n<center>Data from MSKCC, New York</center>\n\n<div>\n\n![](ibrutinib_onset.png)\n\n</div>\n:::\n\n::: {.column width=\"40%\"}\n<br> <br>\n\n-   **In a second, retrospective study from MDACC (2014-2018):**\n    -   21 (2.5%) with proven/probable invasive mold infection\n    -   Primarily pneumonia\n    -   Primary fungus: *Aspergillus* spp.\n    -   Risk factors: monocytopenia, ≥ 3 prior CLL therapies\n:::\n:::\n\n::: aside\n[@varughese2018; @frei2020J]\n:::\n\n## \n\n![](Lancet%20_DI.png)\n\n![](Lancet%20Haematology.png){fig-align=\"center\"}\n\n::: aside\n[@bruggemann2022; @stemler2022J]\n:::\n\n## CYP450 Interactions: The achilles heel of triazoles\n\n<center>75-85% of patients receiving mold-active triazoles have serious drug interactions</center>\n\n![](cyp_interactions.png){fig-align=\"center\" width=\"800\"}\n\n<br>\n\n::: aside\n[@bruggemann2009a; @andes2016]\n:::\n\n## PK/PD Properties of Small Molecule Kinase Inhibitors {.smaller}\n\n<br> <br>\n\n| Drug                  | Venetoclax                   | Midostraurin                 | Gilteritinib                     | Ivosidenib                     | Enasidinib                                                  | Glasdegib                      |\n|-----------------------|------------------------------|------------------------------|----------------------------------|--------------------------------|-------------------------------------------------------------|--------------------------------|\n| Specificity (targets) | BCL2                         | FLT3                         | FLT3                             | IDH1                           | IDH2                                                        | Hedgehog pathway               |\n| Hepatic               | [CYP3A4]{style=\"color:red;\"} | [CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"}   | [CYP3A4/5]{style=\"color:red;\"} | [Multiple CYP enzymes including CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"} |\n| Efflux                | Substrate of PgP, BCRP       | Not a substrate              | Substrate of PgP, not BCRP, OATP | Substrate PgP, but not BRCP    | Not a substrate of BCRP pr PgP                              | Substrate for PGP, BCRP        |\n\n::: aside\n[@megias-vericat2020J]\n:::\n\n## Venetoclax dose-adjustment with triazoles\n\n<br>\n\n<center>\n\nVenetoclax + hypo-methylating agents for AML;\n\nCo-administration with posaconazole ↑ venetoclax AUC 8-fold\n\n</center>\n\n<br>\n\n|          |               |                               |                             |\n|----------|---------------|-------------------------------|-----------------------------|\n| Day      | **Full dose** | **Moderate CYP3A4 inhibitor** | **Strong CYP3A4 inhibitor** |\n| Day 1    | 100 mg        | 50 mg                         | 10 mg                       |\n| Day 2    | 200 mg        | 100 mg                        | 20 mg                       |\n| Day 3    | 400 mg        | 200 mg                        | 50 mg                       |\n| Day 4-28 | 400 mg        | 200 mg                        | 70 mg                       |\n\n::: aside\n[@stemler2022J; @bhatnagar2021J] <br> moderate- fluconazole, isavuconazole; strong- voriconazole, posaconazole\n:::\n\n## Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax\n\n<br>\n\n![](venetoclax_Rausch.png){fig-align=\"center\"}\n\n::: aside\n[@rausch2019]\n:::\n\n## Toxicities of small-molecule kinase inhibitors\n\n![](targeted%20therapy%20toxicities.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@wang2020a]\n:::\n\n## Just avoid triazoles?\n\n<br>\n\n![](avoid%20triazoles.png){fig-align=\"center\"}\n\n## The problems with echinocandin prophylaxis\n\n<br>\n\n![](echinocandin.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@gomes2014]\n:::\n\n## <br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles? {background-image=\"bonemarrow.png\"}\n\n## Triazole toxicities\n\n<br>\n\n![](triazole%20toxicity.png){fig-align=\"center\"}\n\n::: aside\n[@Lewis2011805; @johnson2021]\n:::\n\n## \n\n<br>\n\n![](Ostrosky.png){fig-align=\"center\" width=\"1200\"}\n\n::: aside\n[@ostroskey-zeichnerl2021J]\n:::\n\n## Triazole safety\n\n<br>\n\n-   Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses\n-   Adverse effects leading to treatment discontinuation:\n    -   voriconazole (n=494) 14.2%\n    -   posaconazole (n=547) 11.3%\n    -   isavuconazole (n=514) 3.9%\n    -   multiple/sequenced therapy (n=454) 11.7%\n-   QTc prolongation was rare, but more frequent with voriconazole and posaconazole\n-   Severe drug interactions occurred in 4% of all treated patients\n-   IFI mortality rates were similar for all agents ranging between 1.1-1.8%\n\n::: aside\n[@ostroskey-zeichnerl2021J]\n:::\n\n## What makes isavuconazole <br>(isavuconazonium) unique?\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n<div>\n\n![](isavuconazole.png){fig-align=\"left\" width=\"600\"}\n\n</div>\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n-   Broad spectrum of activity\n-   Prodrug IV/ oral formulations (\\> 90% bioav.)\n-   Predictable linear PK, t~1/2~=130h\n-   Less need for TDM\n-   Better safety profile than voriconazole\n    -   Less potent CYP3A4/5 inhibition\n    -   Less cutaneous, CNS, hepatic toxicities\n    -   Does not prolong QT\n:::\n:::\n\n::: aside\n[@johnson2021; @maertens2016]\n:::\n\n## QT prolongation risk with triazoles\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n![](QTC.png){width=\"400\"}\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n<br>\n\n-   Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K^+^ rectifier current\n-   Isavuconazole shortens cardia QT in a dose-related manner, with no associated cardiac risk\n    -   hCav1.2 L-type Ca^++^ channels\n:::\n:::\n\n::: aside\n[@keirns2017]\n:::\n\n## Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE) {.smaller}\n\n![](Secure.png){fig-align=\"center\" width=\"700\"}\n\n<br>\n\n::: aside\n[@maertens2016]\n:::\n\n## Treatment-emergent adverse effects <br> in the SECURE trial\n\n<br>\n\n-   Hepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)\n-   Visual disturbances (VOR-27% vs. ISA-15%, p=0.002)\n-   Skin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037\n-   **Overall drug-related AE (VOR-60% vs. ISA-42%, p\\<0.001)**\n\n::: aside\n[@maertens2016]\n:::\n\n## Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)\n\n<br>\n\n![](isavuconazole_Mucor.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@marty2014]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| Drug                                | Pharmacokinetic change                      | Initial management                                                                                                    |\n+=====================================+=============================================+=======================================================================================================================+\n| **Tacrolimus**                      | ↑ AUC 1.8-3xfold                            | 40-50% reduction in tacrolimus dose, TDM. Some studies suggest no empiric dose reduction was required                 |\n|                                     |                                             |                                                                                                                       |\n|                                     | ↑ C~max~ 1.4-2.8xfold                       |                                                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| **Prednisone/** <br>**Prednislone** | ↑ AUC (8%) minimal                          | No dose adjustments recommended                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| ::: aside                           | ↑AUC and C~max~ by an average of 27% and 8% | Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with isavuconazole |\n| :::                                 |                                             |                                                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+------------------+-------------------------+--------------------------------------------------------------+\n| Drug             | Pharmacokinetic change  | Initial management                                           |\n+==================+=========================+==============================================================+\n| **Venetoclax**   | ↑AUC 2-3.9xfold         | Dose reduction of venetoclax by 50%                          |\n+------------------+-------------------------+--------------------------------------------------------------+\n| **Midostaurin**  | ↑AUC 1.44xfold higher   | No dose reduction recommended for moderate CYP3A4 inhibitors |\n+------------------+-------------------------+--------------------------------------------------------------+\n| **Gilteritinib** | ↑AUC 1.4xfold; <br>     | No dose reduction recommended for moderate CYP3A4 inhibitors |\n|                  |                         |                                                              |\n|                  | ↑C~max~ 1.2-fold higher |                                                              |\n+------------------+-------------------------+--------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Are the theoretical differences clinically important?\n\n![](Menna_midostraurin.png){fig-align=\"center\"}\n\n::: aside\n[@Menna2021-mb]\n:::\n\n## \n\n![](Bose%20study.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose2.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n##  {.smaller}\n\n![](bose3.png){fig-align=\"center\" width=\"500\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose4.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## Isavuconazole tolerability\n\n<br>\n\n::: columns\n::: {.column width=\"50%\"}\n-   **Posaconazole experience**\n-   [Grade III/IV liver injury with tablet and IV formulations (9%)]{style=\"color:red;\"}\n-   Primary hyperbilirubinemia\n-   Higher frequency in patients with serum levels \\> 1,830 ng/mL\n:::\n\n::: {.column width=\"50%\"}\n-   **Isavuconazole (current study)**\n-   [Grade 1 transaminitis (2.7%)]{style=\"color:red;\"}\n-   Grade 2 elevated T. bilirubin (1.3%)\n-   No elevations in QTc detected vs. baselines at 10 days\n:::\n:::\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose5.png){fig-align=\"center\"}\n\n<br>\n\n<br>\n\n::: aside\n[@Young2021-jx]\n:::\n\n## Jo-Anne H. Young, *Clin Infect Dis 2021*\n\n<br>\n\n<br>\n\n\"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.\n\n<br>\n\n\"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.\"\n\n::: aside\n[@Young2021-jx]\n:::\n\n## Summary {background-image=\"bonemarrow.png\"}\n\n<br>\n\n-   Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario\n-   Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult\n-   Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies\n\n## Thank you for your attention!\n\n![](bologna%202.png){.absolute top=\"200\" left=\"0\" width=\"442\" height=\"303\"}\n\n![](bologna3.png){.absolute top=\"50\" right=\"50\" width=\"450\" height=\"250\"}\n\n![](Screenshot%202022-05-16%20at%2012.30.29.png){.absolute bottom=\"0\" right=\"50\" width=\"418\" height=\"273\"}\n\n## References\n\n<br>\n\nAll figures created by R. Lewis using www.biorender.com <br> <br>\n","srcMarkdownNoYaml":"\n\n## The Changing Landscape of Hematological <br> Malignancy Treatment {background-image=\"bonemarrow.png\"}\n\n<br>\n\n### Implications for antifungal therapy\n\n<br> <br>\n\n<center>Russell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> Infectious Diseases Unit- IRCCS S. Orsola University Hospitals <br> Alma Mater Studiorum Università di Bologna <br> Bologna, Italy</center>\n\n::: aside\nNovember 16, 2022\n:::\n\n## Agenda\n\n<br>\n\n-   How will new therapies for hematological malignancies impact the epidemiology of invasive fungal infections?\n-   What are the risks of toxicity and drug interactions with these newer therapies?\n-   Is their a unique role for isavuconazole vs. other triazoles?\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease                                | Current/future therapies\\*                                                                                                                                     | Survival (5 year) |\n|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|\n| **Hairy cell leukemia**                | Cladarabine + [gemtuzumab ozogamicin (GO)]{style=\"color:red;\"}                                                                                                 | 90%               |\n| **Acute premyelocytic leukemia**       | ATRA + arsenic ± [GO]{style=\"color:red;\"}                                                                                                                      | 80-90%            |\n| **AML (core binding factor positive)** | FLAG-[GO]{style=\"color:red;\"} ± IDA, alloHCT if MRD positive, if indicated, oral [AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors]{style=\"color:red;\"} | 80-90%+           |\n| **AML** <br>**(younger fit)**          | FLAG-IDA and [venetoclax]{style=\"color:red;\"}, CLIA and [venetoclax]{style=\"color:red;\"}                                                                       | 50-60%            |\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\nHMA- hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease                                                                   | Current/ future therapy\\*                                                                                                                   | 5-10 year survival |\n|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------|\n| **AML** <br> **(older, unfit, complex karyotype, T-53 mutations, MECOM)** | Low-intensity triple nucleosides (cladarabine, cytarabine and [HMAs + venetoclax; HMAs + venetoclax + targeted therapy]{style=\"color:red;\"} | 40-50%             |\n| **ALL \\< 60 years**                                                       | HyperCVAD + [CD19/CD20 targeted antibodies]{style=\"color:red;\"}                                                                             | 60-70%             |\n| **ALL \\> 60 years**                                                       | Mini-hyper CVAD+ [inotuzumab; blinatumab + ponatinib]{style=\"color:red;\"}                                                                   | 50%                |\n| **Ph-positive ALL**                                                       | HyperCVAD + [ponatinib; blinatumab + ponatinib]{style=\"color:red;\"}                                                                         | 70-80%?            |\n|                                                                           |                                                                                                                                             |                    |\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\nHMA-hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br> <br>\n\n| Disease | Current/ future therapy\\*                                                                                                 | 5-10 year survival |\n|---------|---------------------------------------------------------------------------------------------------------------------------|--------------------|\n| **CML** | [BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)]{style=\"color:red;\"}, alloHCT | 85-90%             |\n| **CLL** | [Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)]{style=\"color:red;\"}                                 | 80-90% +           |\n| **MDS** | [Parenteral HMAs, oral HMAs, venetoclax, others]{style=\"color:red;\"}                                                      | 40% +              |\n\n::: aside\n[@kantarjian2021] <br>\n\nBTKI- Bruton tyrosine kinase inhibitors, HMA- hypomethylating agent\n\n\\*some therapies investigational or not licensed in Canada\n:::\n\n## <br> <br> <br> <br> <br>How is invasive fungal disease risk altered <br> by targeted therapies? {background-image=\"bonemarrow.png\"}\n\n## Unexpected consequences of targeted therapy?\n\n<br>\n\n![](burger_NEJM.png){fig-align=\"center\" width=\"3028\"}\n\n::: aside\n[@burger2015; @chamilos2018]\n:::\n\n## Ibrutinib-associated aspergillosis\n\n::: columns\n::: {.column width=\"50%\"}\n<br>\n\n<div>\n\n![](MRI.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"50%\"}\n<br>\n\n<br>\n\n-   Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL\n-   [CNS aspergillosis in 11/27 (40%)]{style=\"color:red;\"}, most cases within 3 months of starting therapy\n-   All patients had refractory/relapsed CLL and other predisposing risk factors\n:::\n:::\n\n::: aside\n[@ghez2018; @chamilos2018]\n:::\n\n## Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers\n\n::: columns\n::: {.column width=\"60%\"}\n<center>Data from MSKCC, New York</center>\n\n<div>\n\n![](ibrutinib_onset.png)\n\n</div>\n:::\n\n::: {.column width=\"40%\"}\n<br> <br>\n\n-   **In a second, retrospective study from MDACC (2014-2018):**\n    -   21 (2.5%) with proven/probable invasive mold infection\n    -   Primarily pneumonia\n    -   Primary fungus: *Aspergillus* spp.\n    -   Risk factors: monocytopenia, ≥ 3 prior CLL therapies\n:::\n:::\n\n::: aside\n[@varughese2018; @frei2020J]\n:::\n\n## \n\n![](Lancet%20_DI.png)\n\n![](Lancet%20Haematology.png){fig-align=\"center\"}\n\n::: aside\n[@bruggemann2022; @stemler2022J]\n:::\n\n## CYP450 Interactions: The achilles heel of triazoles\n\n<center>75-85% of patients receiving mold-active triazoles have serious drug interactions</center>\n\n![](cyp_interactions.png){fig-align=\"center\" width=\"800\"}\n\n<br>\n\n::: aside\n[@bruggemann2009a; @andes2016]\n:::\n\n## PK/PD Properties of Small Molecule Kinase Inhibitors {.smaller}\n\n<br> <br>\n\n| Drug                  | Venetoclax                   | Midostraurin                 | Gilteritinib                     | Ivosidenib                     | Enasidinib                                                  | Glasdegib                      |\n|-----------------------|------------------------------|------------------------------|----------------------------------|--------------------------------|-------------------------------------------------------------|--------------------------------|\n| Specificity (targets) | BCL2                         | FLT3                         | FLT3                             | IDH1                           | IDH2                                                        | Hedgehog pathway               |\n| Hepatic               | [CYP3A4]{style=\"color:red;\"} | [CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"}   | [CYP3A4/5]{style=\"color:red;\"} | [Multiple CYP enzymes including CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"} |\n| Efflux                | Substrate of PgP, BCRP       | Not a substrate              | Substrate of PgP, not BCRP, OATP | Substrate PgP, but not BRCP    | Not a substrate of BCRP pr PgP                              | Substrate for PGP, BCRP        |\n\n::: aside\n[@megias-vericat2020J]\n:::\n\n## Venetoclax dose-adjustment with triazoles\n\n<br>\n\n<center>\n\nVenetoclax + hypo-methylating agents for AML;\n\nCo-administration with posaconazole ↑ venetoclax AUC 8-fold\n\n</center>\n\n<br>\n\n|          |               |                               |                             |\n|----------|---------------|-------------------------------|-----------------------------|\n| Day      | **Full dose** | **Moderate CYP3A4 inhibitor** | **Strong CYP3A4 inhibitor** |\n| Day 1    | 100 mg        | 50 mg                         | 10 mg                       |\n| Day 2    | 200 mg        | 100 mg                        | 20 mg                       |\n| Day 3    | 400 mg        | 200 mg                        | 50 mg                       |\n| Day 4-28 | 400 mg        | 200 mg                        | 70 mg                       |\n\n::: aside\n[@stemler2022J; @bhatnagar2021J] <br> moderate- fluconazole, isavuconazole; strong- voriconazole, posaconazole\n:::\n\n## Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax\n\n<br>\n\n![](venetoclax_Rausch.png){fig-align=\"center\"}\n\n::: aside\n[@rausch2019]\n:::\n\n## Toxicities of small-molecule kinase inhibitors\n\n![](targeted%20therapy%20toxicities.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@wang2020a]\n:::\n\n## Just avoid triazoles?\n\n<br>\n\n![](avoid%20triazoles.png){fig-align=\"center\"}\n\n## The problems with echinocandin prophylaxis\n\n<br>\n\n![](echinocandin.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@gomes2014]\n:::\n\n## <br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles? {background-image=\"bonemarrow.png\"}\n\n## Triazole toxicities\n\n<br>\n\n![](triazole%20toxicity.png){fig-align=\"center\"}\n\n::: aside\n[@Lewis2011805; @johnson2021]\n:::\n\n## \n\n<br>\n\n![](Ostrosky.png){fig-align=\"center\" width=\"1200\"}\n\n::: aside\n[@ostroskey-zeichnerl2021J]\n:::\n\n## Triazole safety\n\n<br>\n\n-   Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses\n-   Adverse effects leading to treatment discontinuation:\n    -   voriconazole (n=494) 14.2%\n    -   posaconazole (n=547) 11.3%\n    -   isavuconazole (n=514) 3.9%\n    -   multiple/sequenced therapy (n=454) 11.7%\n-   QTc prolongation was rare, but more frequent with voriconazole and posaconazole\n-   Severe drug interactions occurred in 4% of all treated patients\n-   IFI mortality rates were similar for all agents ranging between 1.1-1.8%\n\n::: aside\n[@ostroskey-zeichnerl2021J]\n:::\n\n## What makes isavuconazole <br>(isavuconazonium) unique?\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n<div>\n\n![](isavuconazole.png){fig-align=\"left\" width=\"600\"}\n\n</div>\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n-   Broad spectrum of activity\n-   Prodrug IV/ oral formulations (\\> 90% bioav.)\n-   Predictable linear PK, t~1/2~=130h\n-   Less need for TDM\n-   Better safety profile than voriconazole\n    -   Less potent CYP3A4/5 inhibition\n    -   Less cutaneous, CNS, hepatic toxicities\n    -   Does not prolong QT\n:::\n:::\n\n::: aside\n[@johnson2021; @maertens2016]\n:::\n\n## QT prolongation risk with triazoles\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n![](QTC.png){width=\"400\"}\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n<br>\n\n-   Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K^+^ rectifier current\n-   Isavuconazole shortens cardia QT in a dose-related manner, with no associated cardiac risk\n    -   hCav1.2 L-type Ca^++^ channels\n:::\n:::\n\n::: aside\n[@keirns2017]\n:::\n\n## Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE) {.smaller}\n\n![](Secure.png){fig-align=\"center\" width=\"700\"}\n\n<br>\n\n::: aside\n[@maertens2016]\n:::\n\n## Treatment-emergent adverse effects <br> in the SECURE trial\n\n<br>\n\n-   Hepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)\n-   Visual disturbances (VOR-27% vs. ISA-15%, p=0.002)\n-   Skin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037\n-   **Overall drug-related AE (VOR-60% vs. ISA-42%, p\\<0.001)**\n\n::: aside\n[@maertens2016]\n:::\n\n## Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)\n\n<br>\n\n![](isavuconazole_Mucor.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@marty2014]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| Drug                                | Pharmacokinetic change                      | Initial management                                                                                                    |\n+=====================================+=============================================+=======================================================================================================================+\n| **Tacrolimus**                      | ↑ AUC 1.8-3xfold                            | 40-50% reduction in tacrolimus dose, TDM. Some studies suggest no empiric dose reduction was required                 |\n|                                     |                                             |                                                                                                                       |\n|                                     | ↑ C~max~ 1.4-2.8xfold                       |                                                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| **Prednisone/** <br>**Prednislone** | ↑ AUC (8%) minimal                          | No dose adjustments recommended                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n| ::: aside                           | ↑AUC and C~max~ by an average of 27% and 8% | Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with isavuconazole |\n| :::                                 |                                             |                                                                                                                       |\n+-------------------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+------------------+-------------------------+--------------------------------------------------------------+\n| Drug             | Pharmacokinetic change  | Initial management                                           |\n+==================+=========================+==============================================================+\n| **Venetoclax**   | ↑AUC 2-3.9xfold         | Dose reduction of venetoclax by 50%                          |\n+------------------+-------------------------+--------------------------------------------------------------+\n| **Midostaurin**  | ↑AUC 1.44xfold higher   | No dose reduction recommended for moderate CYP3A4 inhibitors |\n+------------------+-------------------------+--------------------------------------------------------------+\n| **Gilteritinib** | ↑AUC 1.4xfold; <br>     | No dose reduction recommended for moderate CYP3A4 inhibitors |\n|                  |                         |                                                              |\n|                  | ↑C~max~ 1.2-fold higher |                                                              |\n+------------------+-------------------------+--------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Are the theoretical differences clinically important?\n\n![](Menna_midostraurin.png){fig-align=\"center\"}\n\n::: aside\n[@Menna2021-mb]\n:::\n\n## \n\n![](Bose%20study.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose2.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n##  {.smaller}\n\n![](bose3.png){fig-align=\"center\" width=\"500\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose4.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## Isavuconazole tolerability\n\n<br>\n\n::: columns\n::: {.column width=\"50%\"}\n-   **Posaconazole experience**\n-   [Grade III/IV liver injury with tablet and IV formulations (9%)]{style=\"color:red;\"}\n-   Primary hyperbilirubinemia\n-   Higher frequency in patients with serum levels \\> 1,830 ng/mL\n:::\n\n::: {.column width=\"50%\"}\n-   **Isavuconazole (current study)**\n-   [Grade 1 transaminitis (2.7%)]{style=\"color:red;\"}\n-   Grade 2 elevated T. bilirubin (1.3%)\n-   No elevations in QTc detected vs. baselines at 10 days\n:::\n:::\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose5.png){fig-align=\"center\"}\n\n<br>\n\n<br>\n\n::: aside\n[@Young2021-jx]\n:::\n\n## Jo-Anne H. Young, *Clin Infect Dis 2021*\n\n<br>\n\n<br>\n\n\"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.\n\n<br>\n\n\"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.\"\n\n::: aside\n[@Young2021-jx]\n:::\n\n## Summary {background-image=\"bonemarrow.png\"}\n\n<br>\n\n-   Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario\n-   Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult\n-   Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies\n\n## Thank you for your attention!\n\n![](bologna%202.png){.absolute top=\"200\" left=\"0\" width=\"442\" height=\"303\"}\n\n![](bologna3.png){.absolute top=\"50\" right=\"50\" width=\"450\" height=\"250\"}\n\n![](Screenshot%202022-05-16%20at%2012.30.29.png){.absolute bottom=\"0\" right=\"50\" width=\"418\" height=\"273\"}\n\n## References\n\n<br>\n\nAll figures created by R. Lewis using www.biorender.com <br> <br>\n"},"formats":{"revealjs":{"identifier":{"display-name":"RevealJS","target-format":"revealjs","base-format":"revealjs"},"execute":{"fig-width":10,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":false,"echo":false,"output":true,"warning":false,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"ipynb-shell-interactivity":null,"plotly-connected":true,"engine":"markdown"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":true,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-min-runs":1,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","html-math-method":{"method":"mathjax","url":"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js?config=TeX-AMS_HTML-full"},"slide-level":2,"to":"revealjs","incremental":true,"output-file":"avir talk_ppt.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","tools-share":"Share","tools-download":"Download","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-text-placeholder":"","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words"},"metadata":{"lang":"en","fig-responsive":false,"quarto-version":"1.4.552","auto-stretch":true,"editor":"visual","bibliography":["references.bib"],"touch":true,"controls":true,"transition":"fade","transitionSpeed":"fast","scrollable":true,"slideNumber":true,"multiplex":true,"chalkboard":true,"theme":["default","custom.scss"]}}},"projectFormats":[]}